Novo Nordisk and Eli Lilly dominate AI answers in weight loss market

Novo Nordisk and Eli Lilly have become the loudest names in AI-mediated weight loss discovery, and the gap is wide enough to matter. In 5W Public Relations’ Weight Loss and Metabolic Health AI Visibility Index 2026, five GLP-1 receptor agonist brands, Wegovy, Zepbound, Ozempic, Mounjaro and Saxenda, captured roughly 57% of all category citations across ChatGPT, Claude, Perplexity and Google AI Overviews.

That concentration turns AI tools into a powerful gatekeeper in a market where consumers increasingly ask for explanations, comparisons and treatment ideas before they ever land on a brand site. The index ranks the top 25 U.S. brands in weight loss and metabolic health by citation share, but its sharper message is that AI engines are narrowing the answer surface around a small set of recognizable medicines. Legacy programs and supplements are losing visibility in real time, and the report frames that as a warning for marketers outside the dominant GLP-1 set.

The stakes are higher because 5W says this is not just a brand-awareness contest. It is category ownership inside answer systems, where being absent can mean being excluded from the decision set altogether. In a crowded, regulated field like metabolic health, that affects consumer trust, physician conversations and downstream demand. The firm’s broader research underscores why: a later citation-source study synthesized more than 680 million individual citations across ChatGPT, Google AI Overviews, Perplexity, Gemini and Claude, and found Reddit was the top source across major AI engines, cited at roughly 40% frequency across large language models.

The public-health backdrop helps explain why these answers carry so much weight. Centers for Disease Control and Prevention data show 40.3% of U.S. adults had obesity during August 2021 through August 2023, while 9.4% had severe obesity. That makes GLP-1 medications a mass-market health story, not a niche pharmaceutical one, and the FDA’s recent decisions have only reinforced the category’s dominance.

Zepbound, the tirzepatide brand from Eli Lilly, was approved by the FDA on November 8, 2023 for chronic weight management. Wegovy, from Novo Nordisk, won FDA approval on March 8, 2024 for cardiovascular risk reduction in adults with known heart disease and overweight or obesity. Novo Nordisk later said Ozempic gained a kidney-related indication in adults with type 2 diabetes and chronic kidney disease on January 28, 2025. Saxenda remains an older weight-management brand, but the center of gravity has shifted decisively toward the newer, better-known GLP-1 names.

The pipeline is still moving fast. Reuters reported on May 21, 2026 that Lilly’s experimental obesity drug retatrutide helped patients lose more than 28% of body weight over 1.5 years in a key trial. For AI systems trained on prominence as much as on precision, that kind of momentum only strengthens the same few names. The result is a market where discovery is not broad and open, but highly concentrated, with AI platforms increasingly shaping which brands patients see first and which ones never enter the conversation.